(Q39375083)

11 September 2017

title

Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia (English)

1 reference

11 September 2017

Kentaro Ichioka

1

1 reference

11 September 2017

Hiroki Ohara

2

1 reference

11 September 2017

Naoki Terada

3

1 reference

11 September 2017

Yoshiyuki Matsui

4

1 reference

11 September 2017

Koji Yoshimura

5

1 reference

11 September 2017

Akito Terai

6

1 reference

11 September 2017

Yoichi Arai

7

1 reference

11 September 2017

publication date

1 October 2004

1 reference

International Journal of Urology

11 September 2017

published in

1 reference

11 September 2017

volume

11

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

870-875

1 reference

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Interstitial laser coagulation for management of benign prostatic hyperplasia: a Japanese experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: response durability and variables potentially predicting response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2004.00913.X

Tamsulosin for benign prostatic hyperplasia.

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002081

Identifiers

DOI

10.1111/J.1442-2042.2004.00913.X

1 reference

11 September 2017

1 reference